Project title: further evaluation of AMHR2-ED antigens for epithelial ovarian carcinoma
Ended Awarded Last action
- Contract number
- 75N91021F00002
- Awardee
-
University Of Oklahoma UEI GY8NMUZQXVS7 Part of University Of Oklahoma
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,020,800
Award facts
- Opportunity
-
- TORFP2021E07 Solicitation number
- Contract value 100% obligated
- $1,020,800.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Oklahoma City, OK 73126, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$9,191 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Change Order | $184,150 | |
| Other Administrative Action | $0 | |
| Original award | $845,841 |
About this award
The National Cancer Institute issued a delivery order to the University of Oklahoma's Health Sciences Center on September 15, 2021, with a ceiling value of $1,020,800, for further evaluation of AMHR2-ED antigens for epithelial ovarian carcinoma.
The order is issued under the PREVENT Preclinical Drug Development Program (PREVENT), the National Cancer Institute's standing IDIQ for cancer prevention drug development. Place of performance is Oklahoma City, OK. The ultimate completion date is September 14, 2026.
This is a firm fixed-price delivery order supporting preclinical research into ovarian cancer antigens. Service Contract Inventory reporting shows the order invoiced $1,106,000 across FY2022–FY2025 (FY2022: $193,000 at $104.41/hr; FY2023: $450,000 at $203.17/hr; FY2024: $247,000 at $135.71/hr; FY2025: $216,000). Labor footprint averaged 1.0 FTE annually, with 1.1 FTEs reported in FY2025. Contractor hours totaled 5,886 across reported years. The University of Oklahoma Health Sciences Center self-performed all reported work with no subcontractor engagement.
Quick answers
Who was awarded contract 75N91021F00002?
75N91021F00002 was awarded to University Of Oklahoma by National Cancer Institute (National Institutes of Health) on September 15, 2021.
How much is contract 75N91021F00002 worth?
The government has obligated $1,020,800 on 75N91021F00002.
Is contract 75N91021F00002 an order under another contract?
Yes. 75N91021F00002 is a delivery order under 75N91019D00020, an indefinite delivery contract, on PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91021F00002 competed?
The extent of competition for 75N91021F00002 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award